Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page
- Check2 days agoChange DetectedThe revision label has been updated from v3.5.3 to v3.5.4, signaling a system update. This change does not alter the study content or its presented details.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedClinicalTrials.gov updated the page’s revision/build indicator from v3.5.2 to v3.5.3, reflecting a site version change rather than any changes to the study record.SummaryDifference0.1%

- Check31 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check59 days agoChange DetectedSite revision history shows an addition of v3.5.0 and a deletion of v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check88 days agoChange DetectedThe study record shows new update dates (2026-02-12, 2026-02-17, 2026-08-15) and the field 'Product Manufactured in and Exported from the U.S.' has been removed.SummaryDifference0.5%

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.